Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
How to identify animal tracks, burrows and other signs of wildlife in your neighborhood - 24 Famous Attractions at Disneyland
- 3When Would it be a good idea for you to Look for Help from a Criminal Legal counselor?
- 4Investigating Design and Individual Style: Track down Your Remarkable Look
- 5'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- Wizz CEO: We’re going to invest $1 b. in Israeli market
- A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Independence from the rat race for Recent college grads: Systems and Tips
- The Best Portable Applications for Emotional wellness and Prosperity
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- Fundamental Home Items Each Animal person Needs
- Scientists document a death from a meat allergy tied to certain ticks
